Compare Novartis AG (NVS) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Under Armour Inc Class A — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Under Armour Inc Class A trades at $4.74 (market cap $2.05B). The key difference: Novartis AG is far larger — about 133.7× Under Armour Inc Class A's market cap, and Novartis AG pays a 3.31% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Under Armour Inc Class A for 18 Days on average.
| NVS | UA | |
|---|---|---|
Market Cap | $274.00B | $2.05B |
Volume | 1,852,137 | 3,002,780 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $7.88 |
52-Week Low | $121.80 | $3.96 |
Typical Hold Time | 82 Days | 18 Days |
Enterprise Value | $315.32B | $3.03B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Under Armour (UA) trades at $4.70, down 0.42% with a bearish technical outlook despite recent earnings beats. The company faces significant challenges with negative net income margins (-9.99%) and declining revenue trends, though it maintains a reasonable P/S ratio of 0.41. Recent quarterly results show mixed performance with two beats and one miss, while cash flow remains negative across all categories.
The stock presents high risk with deteriorating fundamentals and negative profitability metrics. While analyst sentiment leans slightly positive with 41% buy ratings, the company's revenue declines and negative cash flow position create substantial headwinds. Investment opportunity exists only for those betting on a successful turnaround strategy execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
